AngioJet Thrombectomy: Weighing the Risks of Kidney Injury
"A new study sheds light on the increased risk of acute kidney injury (AKI) associated with the AngioJet procedure compared to catheter-directed thrombolysis for deep vein thrombosis."
Deep vein thrombosis (DVT), particularly when it affects the iliofemoral veins in the pelvis and legs, is a serious condition that can lead to long-term complications like post-thrombotic syndrome. This syndrome causes chronic pain, swelling, and skin changes, significantly impacting quality of life. To prevent these complications, prompt and effective treatment is essential.
Two common approaches for treating acute iliofemoral DVT are catheter-directed thrombolysis (CDT) and percutaneous pharmacomechanical thrombectomy (PMT). CDT involves delivering clot-dissolving drugs directly to the thrombus through a catheter. PMT, on the other hand, uses mechanical devices to break up and remove the clot, often in conjunction with medication. One such device is the AngioJet system, which utilizes a high-pressure saline jet to fragment and aspirate the thrombus.
While AngioJet offers the advantage of rapid clot removal, recent research suggests it may come with a higher risk of acute kidney injury (AKI) compared to CDT. This article will explore the findings of a new study investigating this potential risk and discuss the implications for patients with iliofemoral DVT.
DVT Burden and AngioJet Utilization
Acute lower extremity deep vein thrombosis (DVT) poses a significant clinical burden due to its association with post-thrombotic syndrome (PTS) and pulmonary embolism (PE). The AngioJet rheolytic thrombectomy system has established clinical utility in treating this condition, though device-related hemolysis and embolic complications remain concerns. Studies comparing AngioJet mechanical thrombectomy with catheter-directed thrombolysis (CDT) have enrolled patient cohorts such as 76 individuals treated at a single center between January and a specified endpoint, evaluating both treatment efficacy and safety profiles.
Conventional Treatment Paradigms
Catheter-directed thrombolysis (CDT) has served as a standard interventional approach for acute lower extremity DVT, delivering thrombolytic agents directly to the clot site. While effective in many cases, this method involves prolonged infusion times and carries bleeding risks associated with thrombolytic therapy. Anticoagulation remains foundational, but does not actively dissolve existing thrombus, leaving some patients at risk for persistent symptoms and post-thrombotic complications.
Evolution of Thrombectomy Approaches
Mechanical thrombectomy devices emerged as alternatives to pharmacological thrombolysis, aiming to reduce bleeding complications while achieving rapid clot removal. The AngioJet system represents one such rheolytic technology that has been refined over time for peripheral vascular applications. Early catheter-directed thrombolysis studies established that early intervention for lower extremity DVT could reduce post-thrombotic morbidity, setting the stage for mechanical adjuncts.
AngioJet vs. CDT: Understanding the Kidney Injury Risk
A study published in the Journal of Vascular Surgery: Venous and Lymphatic Disorders compared the outcomes of patients undergoing AngioJet PMT and CDT for acute iliofemoral DVT. The researchers reviewed the medical records of 198 patients treated at a single center between January 2014 and September 2017. Of these, 79 patients received AngioJet PMT, while 119 underwent CDT.
- AngioJet PMT: Patients undergoing AngioJet PMT had a 2.82 times higher odds of developing AKI compared to those receiving CDT.
- Recent Major Surgery: A history of major surgery within three months of the endovascular intervention was associated with an 8.51 times increased risk of AKI.
- Significant Hematocrit Drop: A decrease in hematocrit (the percentage of red blood cells in the blood) of more than 14% was linked to a 2.73 times higher risk of AKI.
Recent Comparative Effectiveness Studies
A 2026 retrospective single-center study compared AngioJet mechanical thrombectomy versus catheter-directed thrombolysis in acute lower limb DVT, assessing predictors of thrombus clearance, patient experience, and economic impact. Baseline data matching was performed between groups for age, BMI, gender, thrombus type, thrombus location, medical history, onset time, risk factors, and symptom severity level to ensure comparable cohorts. This research aims to clarify which patients benefit most from mechanical thrombectomy versus traditional lytic approaches.
Safety Concerns and Complication Risks
Device-related hemolysis and embolic complications remain significant concerns with AngioJet rheolytic thrombectomy, as noted across multiple analyses. These complications can potentially worsen patient outcomes and offset the procedural benefits of rapid thrombus removal. A 2020 study examined AngioJet as a new therapy alongside catheter-directed thrombolysis, suggesting that clinical selection criteria and operator experience are critical factors influencing safety outcomes.
AngioJet Versus Catheter-Directed Thrombolysis
Direct comparisons between AngioJet mechanical thrombectomy and catheter-directed thrombolysis have been conducted to evaluate both efficacy and safety in acute lower extremity DVT. The AngioJet approach offers potential advantages in procedure time and thrombus removal efficiency, though it introduces specific mechanical complications not seen with pharmacological lysis. Treatment selection between these approaches depends on thrombus characteristics, patient risk profile, and institutional expertise.
Making Informed Decisions About DVT Treatment
The study highlights the importance of carefully weighing the risks and benefits of different treatment options for acute iliofemoral DVT. While AngioJet PMT can be effective for rapid clot removal, the increased risk of AKI, particularly in patients with recent major surgery or those prone to significant hematocrit drops, should be taken into consideration. Patients should discuss these risks with their vascular surgeon to determine the most appropriate treatment strategy for their individual circumstances. Maintaining adequate hydration, using renal protective measures, and closely monitoring kidney function after the procedure are crucial steps to minimize the risk of AKI.
Balancing Efficacy and Safety
The evidence base for AngioJet thrombectomy continues to grow, with comparative studies suggesting it offers a viable alternative to catheter-directed thrombolysis for appropriately selected patients. Clinicians must weigh the benefit of rapid mechanical clot removal against the risk of hemolysis and embolic events when counseling patients. A comprehensive evaluation approach considering thrombus burden, symptom severity, and patient comorbidities appears warranted.
Advancing Mechanical Thrombectomy Technology
Emerging systems such as the Zhongtian SWAM (Synchronized Wave Aspiration and mechanical) thrombectomy device represent next-generation alternatives being evaluated against AngioJet. Future research priorities include refining patient selection criteria, optimizing procedural techniques to minimize complications, and conducting larger multicenter trials. The economic impact of mechanical thrombectomy versus traditional approaches also warrants further investigation to inform healthcare resource allocation.
Clinical Adoption and Access Barriers
Widespread adoption of AngioJet thrombectomy faces challenges including specialized training requirements, equipment costs, and variable institutional experience with mechanical thrombectomy platforms. Healthcare systems must balance investment in advanced interventional technologies against evidence of meaningful patient outcomes improvement. Disparities in access to specialized vascular centers may limit the availability of AngioJet for some patient populations with acute DVT.
Patient Experience and Quality of Life
Beyond clinical efficacy metrics, patient experience factors including procedural recovery time, symptom relief, and avoidance of post-thrombotic syndrome are central to treatment decision-making. Studies incorporating patient-reported outcomes alongside traditional endpoints provide a more complete picture of AngioJet's real-world impact. The goal of reducing long-term morbidity from acute DVT underscores the importance of early, effective intervention tailored to individual patient circumstances.